EMA Authorised: Sarclisa (Isatuximab) — Sanofi Winthrop Industrie

View source ↗

Summary

EMA authorises Sarclisa (isatuximab) for multiple myeloma, expanding treatment options in this area.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• SARCLISA (isatuximab)

Snippet

Status: Authorised. Therapeutic area: Multiple Myeloma. MAH: Sanofi Winthrop Industrie. Decision date: 07/07/2026